Related Experiment Video
Updated: Aug 12, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Estela Pineda1, Marta Domenech2, Ainhoa Hernández2
1Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain.
Oncotargets and Therapy
|February 1, 2023
Summary
Glioblastoma treatment faces significant challenges, including recurrence and lack of effective salvage therapies. Overcoming obstacles in drug delivery, clinical trials, and treatment strategies is crucial for developing better glioblastoma therapies.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
- Clinical Trial Design
Background:
- Glioblastoma (GBM) frequently recurs after first-line treatment, with limited salvage options.
- Recent WHO classification refines prognosis but not treatment strategies for gliomas.
- Disease rarity and specific patient/drug-related issues impede therapeutic advancements.
Purpose of the Study:
- To review current glioblastoma treatments.
- To identify obstacles hindering the development of new glioblastoma therapies.
- To explore promising novel research directions for glioblastoma.
Main Methods:
- Literature review of glioblastoma treatments.
- Analysis of impediments in clinical trials and drug development.
- Examination of emerging research avenues in neuro-oncology.
Main Results:
- Recurrent glioblastoma lacks effective salvage therapy.
- Clinical trial recruitment and efficacy measurement present significant hurdles.
- Drug delivery across the blood-brain barrier and target identification remain challenging.
Conclusions:
- Developing effective glioblastoma treatments requires addressing numerous scientific and logistical obstacles.
- Novel therapeutic strategies and improved clinical trial methodologies are essential.
- Future research must focus on overcoming drug delivery issues and optimizing treatment modalities.
